GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-09-29| Asia-PacificCOVID-19

Shionogi’s COVID-19 Oral Drug and Nasal Vaccine Makes Headway in Trials

by Tyler Chen
Share To

Japan’s Shionogi has made clinical progress on its COVID-19 oral drug and nasal spray vaccine. The Japanese firm said their oral drug entered Phase 2/3 clinical trial on September 27, while the nasal vaccine is expected to head into trials in the 2022 fiscal year.

 

Homegrown COVID-19 Oral Drug in Late-Stage Trial

Shionogi’s COVID-19 oral drug S-217622 is a 3CL protease inhibitor that can block the enzyme critical for virus reproduction. The trial recruited patients with mild or asymptomatic COVID-19, and give them either S-217622 or the placebo once daily for 5 days. The goal is to assess the efficacy and safety data of the antiviral drug.

The firm said that “mild COVID-19 patients or asymptomatic infected persons are mainly treated at home or overnight”, so the oral drug can potentially alleviate the burden on hospitals.

In the Phase 1 trial started in July 2021, S-217622 showed no serious safety issues, and the pharmacokinetics exceeds the target blood drug concentration. In animal models, the viral load quickly dropped after receiving the treatment.

Shionogi also announced the plan to produce 1 million doses of COVID-19 treatment for domestic use by March 2022.

 

Nasal Vaccine in Clinical Trial

On the other hand, Shionogi revealed that their nasal vaccine is scheduled to enter clinical trials in near future. The nasal vaccine is co-developed by Shionogi and the University of Tokyo spinoff HanaVax.

Under the deal signed July 2021, Shionogi will develop the vaccine with HanaVax’s drug delivery system and obtain the exclusive global rights to carry out vaccine research and commercialization. HanaVax will receive an upfront payment and milestones payment from Shionogi.

Additionally, Shionogi is considering launching a clinical trial for a COVID-19 booster shot which can be administered by intramuscular injection. The trial is expected to begin in 2021 and enter the market in March 2022.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
An Interview with AusBiotech CEO Lorraine Chiroiu, Highlighting Innovations and Growth in the Australian Biotech Sector
2023-12-16
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top